Disitamab vedotin plus toripalimab nearly doubled progression-free and overall survival compared to chemotherapy in HER2-expressing la/mUC patients. The combination therapy showed a 64% reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback